GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabpharm Ltd (HKSE:02181) » Definitions » Accounts Payable & Accrued Expense

Mabpharm (HKSE:02181) Accounts Payable & Accrued Expense : HK$117.44 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Mabpharm Accounts Payable & Accrued Expense?

Mabpharm's quarterly accounts payable & accrued expense increased from Dec. 2022 (HK$108.99 Mil) to Jun. 2023 (HK$117.81 Mil) but then declined from Jun. 2023 (HK$117.81 Mil) to Dec. 2023 (HK$117.44 Mil).

Mabpharm's annual accounts payable & accrued expense declined from Dec. 2021 (HK$166.58 Mil) to Dec. 2022 (HK$108.99 Mil) but then increased from Dec. 2022 (HK$108.99 Mil) to Dec. 2023 (HK$117.44 Mil).


Mabpharm Accounts Payable & Accrued Expense Historical Data

The historical data trend for Mabpharm's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mabpharm Accounts Payable & Accrued Expense Chart

Mabpharm Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial 92.88 91.74 166.58 108.99 117.44

Mabpharm Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 166.58 160.43 108.99 117.81 117.44

Mabpharm Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.


Mabpharm (HKSE:02181) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Lujia Road East, Koutai Road West, Block G79, China Medical City, Taizhou, CHN, 225300
Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab).
Executives
Guo Jianjun 2307 Founder of a discretionary trust who can infl
Asia Mabtech Limited
Asia Pacific Immunotech Venture Limited
Guo Family (ptc) Limited
Fortune-healthy Investment Limited
Link Best Capital Limited
Cdh Fund V, L.p.
Cdh Mabtech Limited
Cdh V Holdings Company Limited
China Diamond Holdings Company Limited
China Diamond Holdings V Limited

Mabpharm (HKSE:02181) Headlines

No Headlines